EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy
Cited by 54
Related Papers
IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel
|Nature Communications|2015|170
Stromal induction of BRD4 phosphorylation Results in Chromatin Remodeling and BET inhibitor Resistance in Colorectal Cancer
|Nature Communications|2021|115
HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer
|Proceedings of the National Academy of Sciences|2016|90
RASAL2 activates RAC1 to promote triple-negative breast cancer progression
|Journal of Clinical Investigation|2014|86